DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL Health Logistics" DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cel

DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL

DHL, BONN, Germany and Cryoport,

NASHVILLE, Tenn., (March 31, 2025) - DHL Group ("DHL"), the world's leading logistics provider, and Cryoport, Inc.

(NASDAQ: CYRX) ("Cryoport"), a global provider of supply chain solutions for the life sciences

sector, are pleased to announce that DHL has acquired 100% of CRYOPDP, a leading specialty courier focused on clinical trials, biopharma,

and cell and gene therapies. In this context, the companies also announced a strategic partnership to strengthen their supply chain service

offerings for the global life sciences and healthcare sector.

DHL Group already has an established Life Sciences and Healthcare business,

contributing over EUR 5 billion in global revenue in 2024. Building on this foundation, the acquisition of CRYOPDP marks a significant

step in DHL's commitment to enhancing its capabilities in specialized pharma logistics and expanding the breadth of its offering in the

rapidly growing life science and healthcare sector. CRYOPDP specializes in providing white-glove courier services essential to the sectors

it serves. With operations in 15 countries, CRYOPDP handles over 600,000 shipments per year, servicing customers and patients in over

135 countries worldwide.

Going forward, DHL Supply Chain will further build the potential of

its Pharma Specialized Network solution by leveraging the specialty courier expertise of newly acquired CRYOPDP and the global air capabilities

of DHL Express and DHL Global Forwarding.

The strategic partnership with Cryoport will bring together DHL's

global health logistics capabilities with Cryoport's industry-leading expertise in providing specialized solutions in a fast growing life

science and healthcare market segment. It also deepens DHL's relationship with all the Cryoport business units with respect to specialized

Oscar de Bok, CEO of DHL Supply Chain,

stated, "The acquisition of CRYOPDP is a pivotal move for our supply chain business as we aim to expand our Pharma Specialized Network

to meet the evolving needs of clinical trials, biopharma and cell & gene therapies, in addition to further increasing our footprint

in the conventional pharma and life science healthcare segment. The acquisition of CRYOPDP and the extended partnership with Cryoport

Inc. will enable us to deliver integrated end-to-end solutions, enhancing our service capabilities ."

Jerrell Shelton, CEO of Cryoport, commented

"We are indeed pleased to build on our trusted relationship with the DHL Group. Working together we will bring an enhanced

set of supply chain solutions to meet companies' and patients' critical supply chain needs. This strategic partnership taps

into the strong expertise of DHL's Supply Chain and CRYOPDP, presenting a substantial opportunity for Cryoport to further expand

its reach to global growth markets such as Asia Pacific (APAC) and Europe, Middle East and Africa (EMEA)."

The acquisition aligns with DHL Group's Strategy 2030, which

emphasizes the importance of temperature-controlled networks, first and last mile specialty courier coverage and integrated solutions.

CRYOPDP's capabilities will be instrumental in achieving these objectives and help position DHL as a leader in providing comprehensive

solutions for the pharma industry. This strategic move is also expected to yield cost savings and improve overall service levels, especially

leveraging DHL Express and DHL Global Forwarding air capabilities, ultimately enhancing DHL's footprint in the high-value advanced

For Cryoport, the partnership with DHL will enable it to better execute

its business in EMEA and APAC with a stronger focus on its core business in these regions, creating even greater opportunities to offer

highly targeted, top-tier services in answering market demand for its services and products.

The deal and the outlined partnership are subject to regulatory approvals.

On the internet: group.dhl.com/press

Follow us at: twitter.com/DHLglobal

company for the world

DHL is the leading global brand

in the logistics industry. Our DHL divisions offer an unrivalled portfolio of logistics services ranging from national and international

parcel delivery, e-commerce shipping and fulfillment solutions, international express, road, air and ocean transport to industrial

supply chain management. With about 395,000 employees

in more than 220 countries and territories worldwide, DHL connects people and businesses securely and reliably, enabling global sustainable

trade flows. With specialized solutions for growth markets and industries including technology, life sciences and healthcare, engineering,

manufacturing & energy, auto-mobility and retail, DHL is decisively positioned as "The logistics company for the world".

DHL is part of DHL Group. The Group generated revenues of more than

81.8 billion euros in 2023. With sustainable business practices and a commitment to society and the environment, the Group makes

a positive contribution to the world. DHL Group aims to achieve net-zero emissions logistics by 2050.

About Cryoport, Inc.

Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply

chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers

(CDMOs), contract research organizations (CROs), developers, and researchers to carry out their respective business with products and

services that are designed to derisk services and provide certainty. We provide a broad array of supply chain solutions for the life

sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics,

specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are "Enabling the Future of Medicine "

worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.

Our corporate headquarters, located in Nashville, Tennessee, is complemented

by over 50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the Netherlands, Belgium, Portugal,

Germany, Japan, Australia, India, and China.

For more information, visit www.cryoportinc.com or follow via

LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.twitter.com/cryoport

Forward-Looking Statements

Statements in this press release which are not purely historical, including

statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of

the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking

statements include, but are not limited to, those related to Cryoport's expectations about future benefits of the sale of CRYOPDP and

the strategic collaboration with DHL, including the potential impact on future revenue and revenue streams. It is important to note that

Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual

results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic

and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in

the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's

business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section

of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking

statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance

on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or

revise any forward-looking statements in this press release.